Comparisons between GBS subtypes are shown in Tables Tables33 and and4.4. There were no significant differences in the clinical features between the GBS subtypes with the exception that there was a higher proportion of patients who were able to walk independently at the time of admission in the AIDP subtype compared to that in the axonal subtype (combined AMAN and AMSAN). Patients with AMSAN were significantly more likely to have oropharyngeal weakness than those with AMAN. An antecedent URTI was more frequent in patients with AIDP compared to those with the axonal subtype, and diarrhea was more frequent in patients with AMAN compared to those with AMSAN. CSF protein level was significantly lower in patients with AMAN (median, 0.5 g/L; IQR, 0.32–0.86) than in patients with AIDP (median, 0.8 g/L; IQR, 0.51–1.4; Bonferroni-corrected P = 0.05) and AMSAN (median 0.93 g/L; IQR, 0.59–2.4; Bonferroni-corrected P = 0.036).

Clinical and laboratory characteristics and outcome comparing axonal versus demyelinating subtypes of GBS

*CSF protein level was higher in AIDP than in AMAN (median, 0.5; IQR, 0.32–0.86), Bonferroni-corrected P = 0.05

Clinical and laboratory characteristics and outcome comparing AMAN versus AMSAN subtypes of GBS

*Bonferroni-corrected

Regarding hospital course, there were more frequent repeated therapy, ICU admission, mechanical ventilation, and tracheostomy and longer duration of hospitalization in patients with the axonal subtype compared to those with AIDP, Table Table3.3. These variables and duration of ICU stay were also more frequent in patients with AMSAN compared to those in patients with AMAN, Table Table4.4. Despite the shorter follow-up period in patients with AIDP, a higher proportion of these patients were able to walk independently at follow-up compared to those with the axonal subtype.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.